Wells Fargo Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
Get Alerts BMRN Hot Sheet
Price: $91.20 -0.93%
Rating Summary:
23 Buy, 10 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
23 Buy, 10 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Wells Fargo upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Market Perform to Outperform with a price target of $103-$107 (from $72-$76). Analyst Brian Abrahams is positive ahead of 2015 data. He also thinks the company is an attractive M&A candidate.
For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.
Shares of BioMarin Pharmaceutical Inc. closed at $82.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
- RBC Capital Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Outperform
- BioMarin Pharma (BMRN) Tops Q1 EPS by 39c ; Offers Guidance
Create E-mail Alert Related Categories
Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!